varicella vaccine + MMR vaccine

This refers to the co-administration of the live attenuated varicella vaccine and the measles, mumps, and rubella (MMR) vaccine, as evaluated in clinical research by the Shanghai Municipal Center for Disease Control and Prevention. The varicella vaccine component typically contains the live-attenuated varicella-zoster virus (Oka strain), while the MMR vaccine is a trivalent vaccine containing live-attenuated measles, mumps, and rubella viruses. This co-administration strategy is intended to provide simultaneous protection against all four viral pathogens, thereby simplifying pediatric immunization schedules. A Phase 4 study (NCT02685202) was conducted to assess the safety, immunogenicity, and effectiveness of this combination, specifically focusing on whether simultaneous administration affects the antibody response to the varicella component compared to sequential dosing.

Other names

varicella vaccine and MMR vaccine co-administration